Search Results - "De Swert, Heidi"

Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6) by Meyskens, Thomas, Metzger, Otto, Poncet, Coralie, Goulioti, Theodora, Xenophontos, Eleni, Carey, Lisa A., Wang, Lei, Rossi, Giovanna, Gilham, Leslie, De Swert, Heidi, Casas-Martin, Jose, Attieh, Elham, Arahmani, Amal, De Meulemeester, Laura, Partridge, Ann H., Herold, Christina Isabella, Paux, Gautier, Dueck, Amylou C., Brain, Etienne, Cameron, David A.

“…TPS607 Background: There are currently limited treatment options for patients with HR+ EBC who have discontinued adjuvant treatment with aromatase inhibitors…”
Get full text

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant by Malorni, Luca, Tyekucheva, Svitlana, Hilbers, Florentine S., Ignatiadis, Michail, Neven, Patrick, Colleoni, Marco, Henry, Stéphanie, Ballestrero, Alberto, Bonetti, Andrea, Jerusalem, Guy, Papadimitriou, Konstantinos, Bernardo, Antonio, Seles, Elena, Duhoux, Francois P., MacPherson, Iain R., Thomson, Alastair, Davies, David Mark, Bergqvist, Mattias, Migliaccio, Ilenia, Gebhart, Géraldine, Zoppoli, Gabriele, Bliss, Judith M., Benelli, Matteo, McCartney, Amelia, Kammler, Roswitha, De Swert, Heidi, Ruepp, Barbara, Fumagalli, Debora, Maibach, Rudolf, Cameron, David, Loi, Sherene, Piccart, Martine, Regan, Meredith M.

“…Biomarkers for cyclin-dependent kinase 4/6 inhibitors, such as palbociclib, for patients with hormone receptor-positive/HER2-negative metastatic breast…”
Get full text

Abstract PS5-05: Serum thymidine kinase activity in patients with luminal metastatic breast cancer treated with palbociclib and fulvestrant within the PYTHIA trial by Malorni, Luca, Tyekucheva, Svitlana, Hilbers, Florentine S, Ignatiadis, Michail, Neven, Patrick, Colleoni, Marco, Henry, Stéphanie, Ballestrero, Alberto, Bonetti, Andrea, Jerusalem, Guy, Papadimitriou, Konstantinos, Bernardo, Antonio, Duhoux, Francois, MacPherson, Iain, Thomson, Alastair, Davies, David Mark, Bergqvist, Mattias, Benelli, Matteo, McCartney, Amelia, De Swert, Heidi, Ruepp, Barbara, Rabaglio, Manuela, Maibach, Rudolf, Piccart, Martine, Regan, Meredith M

“…Background: The CDK4/6 inhibitor palbociclib (P) plus fulvestrant (F) is approved for the treatment of patients (pts) with luminal metastatic breast cancer…”
Get full text

Abstract PO3-13-02: Genomic and intrinsic subtype correlates of serum thymidine kinase activity in patients with metastatic breast cancer treated with palbociclib and fulvestrant in the PYTHIA trial by Tyekucheva, Svitlana, Crestani, Thayane, Ignatiadis, Michail, Neven, Patrick, Colleoni, Marco, Henry, Stéphanie, Papadimitriou, Konstantinos, Bernardo, Antonio, Seles, Elena, Duhoux, Francois, Macpherson, Iain, Thomson, Alastair, Davies, David Mark, Bergqvist, Mattias, Migliaccio, Ilenia, Zoppoli, Gabriele, Kammler, Roswitha, De Swert, Heidi, Ruepp, Barbara, Guerrero, Angel, Llinas, Arnau, Fimereli, Danai, Arahmani, Amal, Cameron, David, Loi, Sherene, Piccart, Martine, Regan, Meredith, Benelli, Matteo, Malorni, Luca

“…Background: Serum thymidine kinase activity (sTKa) is a novel non-invasive proliferation biomarker providing prognostic, predictive and monitoring information…”
Get full text

Abstract PO2-16-02: RBsig gene-expression signature in patients with endocrine resistant metastatic breast cancer treated with palbociclib and fulvestrant in the PYTHIA trial by Benelli, Matteo, Tyekucheva, Svitlana, Crestani, Thayane, Ignatiadis, Michail, Neven, Patrick, Colleoni, Marco, Henry, Stéphanie, Papadimitriou, Konstantinos, Bernardo, Antonio, Seles, Elena, Duhoux, François, Macpherson, Iain, Thomson, Alastair, Davies, David Mark, Migliaccio, Ilenia, Zoppoli, Gabriele, Kammler, Roswitha, De Swert, Heidi, Ruepp, Barbara, Aftimos, Philippe, Seoane, Jose, Romagnoli, Dario, Venet, David, Goulioti, Theodora, Cameron, David, Loi, Sherene, Piccart, Martine, Regan, Meredith, Malorni, Luca

“…Background: We have previously identified RBsig, a gene-expression signature of resistance to CDK4/6 inhibitors composed of E2F1/E2F2 dependent genes, which is…”
Get full text

Human challenge studies in healthy volunteers: practical considerations and outcomes of influenza trials by Mfopou, Josué K., Memoli, Gaël, Pillu, Haiko, De Swert, Heidi, De Cock, Patricia

“…Abstract only…”
Get full text

Abstract OT1-04-01: AMEERA-6: Phase 3 Study of Adjuvant Amcenestrant Versus Tamoxifen for Patients With Hormone Receptor-Positive Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity by Metzger, Otto, Herold, Christina, Poncet, Coralie, De Swert, Heidi, Casas-Martin, Jose, Partridge, Ann, Guita, Samia, Carey, Lisa, Schumacher, Eva, Goulioti, Theodora, Meyskens, Thomas, Gannon, Joseph, Benlhassan, Khadija, Rossi, Giovanna, Xenophontos, Eleni, Arahmani, Amal, Dueck, Amylou C., Paux, Gautier, Brain, Etienne, Cameron, David A.

“…Background: About 30% of patients (pts) with hormone receptor (HR)-positive early breast cancer (EBC) on adjuvant aromatase inhibitor (AI) therapy discontinue…”
Get full text